Bimzlex
Indication: Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa
Population PK simulator for bimekizumab (BIMZELX), a dual IL-17A/IL-17F-neutralizing monoclonal antibody used for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Explore subcutaneous dosing regimens and exposure profiles based on published clinical pharmacology data.
Drug Overview
Clinical Context
- Molecular Target
- IL-17A and IL-17F
- Drug Class
- IL-17A/IL-17F monoclonal antibody
- Therapeutic Area
- Immunology / Dermatology / Rheumatology
- Indication
- Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa
- Route of Administration
- Subcutaneous
Model Information
- Model Type
- Population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Bimzlex allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK model characterizes the pharmacokinetics of this il-17a/il-17f monoclonal antibody following subcutaneous administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Bimzlex PK simulator?
This is a free, interactive pharmacokinetic simulator for Bimzlex used in Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Bimzlex belong to?
Bimzlex is classified as a IL-17A/IL-17F monoclonal antibody that targets IL-17A and IL-17F. It is used in the Immunology / Dermatology / Rheumatology therapeutic area.
What route of administration does this model simulate?
This simulator models Subcutaneous administration of Bimzlex. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Bimzlex simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community